Company: PBH
Filing Date: 2025-05-09
Form Type: 10-K
Source: 0001295947-25-000017
Chunk: 77

Company: Prestige Consumer Healthcare Inc.
Filing Date: 2025-05-09
Form: 10-K
Item: Item 7
Chunk 77
---
9 million related to non-strategic finite-lived assets.  The impairments primarily reflected the deliberate shift in sales toward other strategic brands within our portfolio.  Of the total charges, $10.0 million pertain to our North American OTC Healthcare segment, while $2.5 million relates to our International OTC Healthcare segment.

Interest Expense, Net

Interest expense, net was $47.6 million during 2025 versus $67.2 million during 2024.  The average cost of borrowing decreased to 4.7% for 2025 from 5.4% for 2024.  The average indebtedness decreased to $1.1 billion during 2025 from $1.3 billion in 2024.  

Income Taxes 

The provision for income taxes during 2025 was $69.6 million versus $66.7 million in 2024.  The effective tax rate on income before income taxes was 24.5% during 2025 versus 24.2% during 2024.  The increase in the effective tax rate in 2025 compared to 2024 was due to the mix of earnings in the U.S. and foreign jurisdictions.  

Results of Operations 

2024 compared to 2023 For a discussion of fiscal 2024 compared to 2023, please refer to Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations of our 2024 Annual Report on Form 10-K, filed with the SEC on May 15, 2024. 

Liquidity and Capital Resources

Liquidity

Our primary source of cash comes from our cash flow from operations.  In the past, we have supplemented this source of cash with various debt facilities, primarily in connection with acquisitions.  We have financed our operations, and expect to continue to finance our operations over the next twelve months, with a combination of funds generated from operations and borrowings.  Our principal uses of cash are for operating expenses, debt service, capital expenditures, share repurchases and acquisitions.  Based on our current levels of operations and anticipated growth, excluding acquisitions, we believe that our cash generated from operations and our existing credit facilities will be adequate to finance our working capital and capital expenditures through the next twelve months, although no assurance can be given in this regard.  See "Economic Environment" above with respect to current uncertainties facing us from a liquidity perspective.

 Year Ended March 31,$ Change(In